[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National University Hospital, Singapore\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":707},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,69,0,25,[9,57,88,114,148,175,199,225,248,278,305,328,365,392,417,445,475,495,516,535,561,599,635,664,687],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":4},"100629926","a-randomised-controlled-trial-of-eprom-guided-flexible-scheduling-in-dermatology-100629926",false,"NCT07481019","A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology","Inclusion Criteria:\n\n* Dermatology outpatients otherwise due for a follow-up appointment within six months.\n* Ability to independently navigate and complete ePROMs.\n* Ability to provide informed consent (including parental consent for minors).\n\nExclusion Criteria:\n\n* Patients who require fixed or scheduled in-person visits, including those needing skin cancer surveillance, bedside procedures (e.g., liquid nitrogen therapy), surgical interventions, or routine blood tests for immunosuppressive therapy.","ALL","16 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to evaluate whether an electronic patient-reported outcome measure (ePROM)-guided flexible scheduling system can improve outpatient clinic resource utilisation in patients attending dermatology outpatient clinics for routine follow-up. The main questions it aims to answer are:\n\n* Does the intervention reduce the number of actualised outpatient visits over 12 months compared with standard fixed scheduling?\n* Does the intervention group achieve higher adherence to monthly ePROM monitoring, as measured by the proportion of completed ePROM submissions?",[26,27,28,29,30],"Chronic Dermatological Conditions","Eczema","Urticaria","Psoriasis","Acne",[32,33,34,35,36,37,38,39,40,41,42,43,44],"dermatology","flexible scheduling","patient initiated follow up","electronic patient-reported outcomes","ePROMs","Bayesian decision support","outpatient care","health services research","randomised controlled trial","implementation science","healthcare utilisation","appointment no-shows","value-based care","NOT_YET_RECRUITING","2026-06-29",{"date":48,"type":49},"2026-07-01","ACTUAL",{"date":51,"type":20},"2026-09",{"date":53,"type":20},"2029-12",{"name":55,"class":56},"National University Hospital, Singapore","OTHER",{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":21,"phases":67,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100611941","developing-and-testing-the-effectiveness-of-a-skin-cancer-self-detection-educational-program-100611941","NCT07247123","Developing and Testing the Effectiveness of a Skin Cancer Self-Detection Educational Program","Protocol for Developing and Testing the Effectiveness of a Skin Cancer Self-Detection Educational Program: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Individuals aged 16 and above\n* Able to read and converse in English\n* Able to provide informed consent\n* Having the ability to use and interact with a web server or application.\n\nExclusion Criteria:\n\n\\- Individuals who have cognitive impairment or decline to participate. There will be no exclusion criteria based on a previous history of skin cancer.",true,{"count":66,"type":20},280,[23],"Skin cancer is a significant public health concern, even in an Asian society like Singapore where it ranks among the top 10 cancers. This RCT tests the effectiveness of a skin cancer educational intervention to improve skin cancer outcomes among skin-of-color individuals, including the effects of gain versus loss framing.",[70,71,72],"Skin Cancer","Skin Cancer Prevention","Benign Skin Growth",[74,75,76,77,78],"skin cancer","skin cancer education","skin cancer intervention","patient education","digital education","RECRUITING",{"date":81,"type":49},"2026-06-30",{"date":83,"type":49},"2026-06-15",{"date":85,"type":20},"2027-12",{"name":55,"class":56},1,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":87},"100570057","use-of-a-digital-psychotherapeutic-app-to-reduce-symptom-burden-in-dermatology-patients-100570057","NCT06702293","Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients","Development and Testing of a Digital Psychological Tool to Improve Symptom Burden in Dermatology Patients","Inclusion Criteria:\n\n* Patients with psoriasis, eczema or chronic urticaria diagnosed by a dermatologist\n* Aged 16 or older\n* Peak pruritus intensity of 4 or more on a 11-point numerical rating scale (0-10, with 10 representing worst itch)\n* Able to engage with a mobile application in the English language\n\nExclusion Criteria:\n\n* Patients with active psychiatric symptoms (e.g. active suicidal ideation, psychosis, delusions)\n* Patients with unstable psychiatric condition, characterized by\n\n  o Hospital inpatient admission for a psychiatric condition or initiation of a psychotropic medication in the prior 3 months\n* Patients with unstable dermatological condition, characterized by\n\n  * Recent flare of the skin condition within the last 2 weeks, including diagnosis of a flare by a doctor, use of systemic steroids, oral antibiotics, wet wrap rescue therapy, oral antivirals, or increase in frequency of phototherapy or dose of systemic medications for the dermatological condition within the last 2 weeks OR\n  * Any of the following within 3 months\n\n    * inpatient admission for a dermatological condition\n    * Initiation of phototherapy\n    * Initiation of systemic therapy (conventional immunosuppressive agent, biologics, JAK inhibitors) within the last 3 months.",{"count":96,"type":20},690,[23],"Skin diseases, despite low mortality, significantly impair quality of life. This randomised controlled trial evaluates the efficacy of a digital toolkit comprising psychotherapeutic strategies in reducing QoL burden in patients with chronic inflammatory skin conditions. This toolkit is hosted on a mobile application and will be used by study participants randomised to the intervention arm over the 32 week study period.",[27,29,28],[101,102,103,104,105,106,107],"digital health","eczema","psoriasis","urticaria","healthservices research","digital","mental health",{"date":48,"type":49},{"date":110,"type":49},"2026-02-23",{"date":112,"type":20},"2029-07",{"name":55,"class":56},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":128,"conditions":129,"keywords":134,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":87},"100645329","phase-1-tislelizumab-in-combination-with-bevacizumab-and-capecitabine-in-advanced-solid-tumors-with-evaluation-in-immunotherapy-resistant-and-central-nervous-system-disease-100645329","NCT07681297","Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease","Phase Ib\u002FII Study of Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease (TIBEC)","TIBEC","Inclusion Criteria:\n\nPatients are eligible for enrolment if they meet all applicable general inclusion criteria and, where relevant, the cohort-specific inclusion criteria.\n\n1. General Inclusion Criteria\n\n   * Age 21 years or older at the time of informed consent.\n   * Histologically or cytologically confirmed advanced or metastatic solid tumor.\n   * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n   * Estimated life expectancy of at least 12 weeks.\n   * At least one evaluable (measurable or non-measurable) lesion as defined by RECIST version 1.1, unless otherwise specified for a disease-specific cohort.\n   * Recovery to Grade 1 or baseline from acute toxicities of prior anti-cancer therapy, except for alopecia, vitiligo, or other toxicities deemed not clinically significant by the investigator.\n   * Adequate organ and marrow function within 14 days prior to first dose of study treatment, defined as follows:\n\n     1. Absolute neutrophil count ≥1.5 × 10\\^9\u002FL\n     2. Platelet count ≥100 × 10\\^9\u002FL\n     3. Haemoglobin ≥9.0 g\u002FdL\n     4. Total bilirubin \\\u003C1.5 × upper limit of normal, except in patients with known Gilbert's syndrome, in whom total bilirubin up to 3.0 × upper limit of normal is permitted provided direct bilirubin is within normal limits\n     5. AST and ALT \\\u003C2.5 × upper limit of normal, or \\\u003C5 × upper limit of normal in the presence of liver metastases\n     6. Calculated creatinine clearance ≥50 mL\u002Fmin (calculated using the Cockcroft-Gault formula)\n     7. Urine protein dipstick \\\u003C2+, or if urine dipstick is 2+ or greater, 24-hour urine protein \\\u003C1 g per 24 hours\n   * Adequately controlled blood pressure (systolic \\\u003C150mmHg, diastolic \\\u003C100mmHg) with or without anti-hypertensive medication.\n   * Able to swallow and retain oral medication.\n   * Able to understand and willing to sign written informed consent.\n   * Willing and able to comply with study visits, treatment plan, laboratory tests, imaging, and other protocol-required procedures.\n   * Prior exposure to immune checkpoint inhibitors, anti-angiogenic therapy, or fluoropyrimidines is permitted, unless prohibited by cohort-specific criteria.\n2. TNBC Cohort Inclusion Criteria\n\n   * Histologically confirmed triple-negative breast cancer, defined as estrogen receptor \\\u003C1%, progesterone receptor \\\u003C1%, and HER2-negative according to current ASCO\u002FCAP guidelines.\n   * Metastatic or unresectable locally advanced disease not amenable to curative treatment.\n   * PD-L1-negative disease, defined as combined positive score (CPS) \\\u003C10 using an approved assay.\n   * Candidate for first-line systemic therapy for metastatic disease.\n   * Patients must have measurable or non-measurable but evaluable disease per RECIST v1.1.\n   * Patients without measurable disease may be enrolled provided they have unequivocal non-measurable disease that can be adequately assessed or disease status on serial radiologic evaluations, in the opinion of the investigator.\n   * Prior neoadjuvant or adjuvant chemotherapy is permitted.\n   * Prior immune checkpoint inhibitor therapy in the neoadjuvant or adjuvant setting is permitted, provided it was completed at least 12 months prior to start of study treatment.\n   * Prior capecitabine is permitted only in the adjuvant setting, provided it was completed at least 12 months prior to start of study treatment.\n   * Patients with prior CNS disease are eligible only if CNS disease is clinically controlled, defined as asymptomatic or minimally symptomatic, does not require corticosteroids and does not require ongoing CNS-directed therapy.\n3. CNS Cohort Inclusion Criteria\n\n   * Histologically or cytologically confirmed advanced solid tumor.\n   * Progressive brain metastases.\n   * At least one measurable CNS lesion.\n   * Leptomeningeal disease is allowed.\n   * Patients receiving corticosteroids for management of CNS disease or CNS-related symptoms are eligible provided the corticosteroid dose is stable or decreasing for at least 7 days prior to first dose of study treatment.\n   * Patients with driver mutations (e.g., EGFR-mutant or ALK-rearranged NSCLC, HER2+ metastatic breast cancer) must have received at least one prior line of matched systemic therapy, unless such therapy is contraindicated, not tolerated, unavailable, or the patient is otherwise unsuitable in the investigator's judgment.\n4. HR-Positive\u002FHER2-Negative Cohort Inclusion Criteria\n\n   * Histologically confirmed hormone receptor-positive (defined as ER\\>1% or PR\\>1%), HER2-negative metastatic or unresectable locally advanced breast cancer not amenable to curative treatment.\n   * Patients must have measurable or non-measurable but evaluable disease per RECIST v1.1.\n   * Patients without measurable disease may be enrolled provided they have unequivocal non-measurable disease that can be adequately assessed or disease status on serial radiologic evaluations, in the opinion of the investigator.\n   * Prior failure of at least one line of endocrine therapy in the advanced or metastatic setting, unless deemed endocrine-resistant in the opinion of the investigator.\n   * Up to one prior line of palliative chemotherapy is permitted.\n   * If prior capecitabine was given, it must not have been administered in the metastatic setting and must have been completed \\>12 months prior to study entry.\n   * Any CNS disease must be clinically controlled, defined as asymptomatic or minimally symptomatic, must not require corticosteroids, and must not require ongoing CNS-directed therapy.\n\nExclusion Criteria:\n\nPatients will be excluded if they meet any applicable general exclusion criterion or any relevant cohort-specific exclusion criterion.\n\n1. General Exclusion Criteria\n\n   * Treatment with an investigational agent within 14 days prior to first dose of study treatment.\n   * Known hypersensitivity or contraindication to tislelizumab, bevacizumab, capecitabine, fluoropyrimidines, or any excipients of the study drugs.\n   * Known clinically significant dihydropyrimidine dehydrogenase deficiency.\n   * Uncontrolled or clinically unstable CNS disease, including poor performance status attributable to CNS disease, ongoing requirement for escalating corticosteroids, uncontrolled seizures, or rapid neurologic deterioration.\n   * Clinically significant cardiovascular disease, including uncontrolled hypertension, unstable angina, clinically significant arrhythmia, myocardial infarction, or stroke that is of clinical concern in the opinion of the investigator.\n   * Significant bleeding risk or recent clinically significant hemorrhage.\n   * History of gastrointestinal perforation, fistula, or intra-abdominal abscess within 6 months prior to first dose, or other conditions conferring high risk in the opinion of the investigator.\n   * Non-healing wound, active ulcer, or untreated fracture.\n   * Active infection requiring systemic therapy.\n   * Active autoimmune disease requiring systemic immunosuppressive treatment within the past 2 years, with exceptions such as replacement therapy or other conditions judged unlikely to recur.\n   * Current use of systemic immunosuppressive medication, excluding physiologic corticosteroid replacement or other permitted low-dose steroids.\n   * Active pneumonitis or interstitial lung disease requiring treatment, or other clinically significant pulmonary condition that, in the opinion of the investigator, would increase the risk of study treatment.\n   * Other active malignancy requiring treatment or likely to interfere with assessment of study endpoints, in the opinion of the investigator.\n   * Pregnancy or breastfeeding.\n   * Any serious medical, psychiatric, or social condition that, in the opinion of the investigator, would compromise patient safety, interfere with study participation, or confound interpretation of study results.\n2. TNBC Cohort Exclusion Criteria\n\n   * Prior systemic therapy for metastatic TNBC.\n   * Prior capecitabine in the metastatic setting.\n   * Progressive CNS disease. Patients with progressive CNS disease should be enrolled into the CNS cohort instead.\n3. CNS Cohort Exclusion Criteria\n\n   * Severely symptomatic or clinically unstable CNS disease, including rapid neurologic deterioration, uncontrolled seizures, or requirement for rapidly escalating corticosteroids.\n   * CNS disease requiring immediate neurosurgical intervention or urgent radiation therapy, in the opinion of the investigator.\n   * Stereotactic radiosurgery (SRS) including gamma knife, within 7 days before the first dose of study treatment.\n   * Whole brain radiotherapy (WBRT) within 21 days before the first dose of study treatment.\n   * Use of checkpoint inhibitor, bevacizumab, and\u002For capecitabine within 6 months before the first dose of study treatment.\n4. HR-Positive\u002FHER2-Negative Cohort Exclusion Criteria\n\n   * More than one prior line of palliative chemotherapy.\n   * Progressive CNS disease. Patients with progressive CNS disease should be enrolled into the CNS cohort instead.","21 Years",{"count":124,"type":20},154,[126,127],"PHASE1","PHASE2","This study is designed to establish the safety of the combination of PD-1 inhibitor tislelizumab, an anti-angiogenic agent bevacizumab and a chemotherapeutic agent capecitabine, in a phase Ib setting and to evaluate preliminary efficacy in selected expansion cohorts, including PD-L1-negative metastatic triple negative breast cancer (TNBC) and patients with active CNS disease. A sequential approach to cohort expansion will allow further evaluation in hormone receptor positive (HR+), HER2 negative (HER2-) disease if a signal of activity is observed in PD-L1 negative TNBC.",[130,131,132,133],"Advanced Solid Tumor Cancer","Triple-Negative Breast Cancer (TNBC)","CNS Disease","Breast Cancer",[135,136,137,133,138,139,131],"Tislelizumab","Bevacizumab","Capecitabine","Advanced Solid Tumour Cancer","CNS disease","2026-06-26",{"date":142,"type":49},"2026-07-02",{"date":144,"type":20},"2026-08",{"date":146,"type":20},"2028-08",{"name":55,"class":56},{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":158,"conditions":159,"keywords":166,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":87},"100644717","evaluating-the-optimal-timing-of-acupuncture-for-managing-chemoradiation-induced-xerostomia-in-patients-with-head-and-neck-cancers-100644717","NCT07674706","Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers","A Pilot Randomised Trial Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all the following criteria apply:\n\n1. Aged 21 years or older\n2. Oral cavity or oropharyngeal squamous cell carcinoma, or nasopharyngeal carcinoma planned for either curative adjuvant or definitive chemoradiotherapy using intensity-modulated radiation therapy (IMRT).\n\n   Participants who have received prior induction chemotherapy or are planned for adjuvant chemotherapy are not excluded.\n3. Anatomically intact parotid and submandibular glands\n4. Eastern Cooperative Oncology Group performance status of 0 to 2\n5. Able to provide informed consent\n6. A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:\n\n   1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR\n   2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the acupuncture period and for at least 28 days after the last acupuncture.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. History of xerostomia, Sjögren's disease, or another underlying systemic illness known to cause xerostomia\n2. Prior head and neck radiation treatment\n3. Has bleeding disorders (e.g. Hemophilia), or on anticoagulants (e.g. warfarin, low molecular weight heparin and novel oral anticoagulants)\n4. Upper or lower extremity deformities that could interfere with accurate acupoint location or alter the energy pathway as defined by traditional acupuncture theory.\n5. Local skin infections, lymphedema, or severe skin conditions (e.g., psoriasis, eczema) at or near the acupuncture sites\n6. Ongoing active systemic infection\n7. Current use of amifostine or cholinergic agonist medications (pilocarpine, cevimeline) that can affect salivary functions (salivary substitute not prohibited, but if using, they must refrain from using it for at least 24 hours prior to salivary flow assessment)\n8. Concurrent use of alternative medicines (e.g., Chinese Propriety medicines), that could affect salivary function\n9. Is pregnant or expecting to conceive within the projected duration of the trial, starting with the screening visit through 28 days after the last acupuncture treatment\n10. Low body mass index, ie. BMI \\\u003C 15\n11. Mental incapacitation or significant emotional or psychiatric disorder that, in the opinion of the investigator, may prevent the patient from cooperating with trial procedures",{"count":156,"type":20},50,[23],"While existing data supports the use of acupuncture to reduce radiation-induced xerostomia, the optimal timing of acupuncture for managing chemoradiation-induced xerostomia remains an area of active investigation. Prior studies have administered acupuncture either in patients who developed xerostomia 12 months after radiation 10 or during the radiation therapy itself 9. The hypothesis is that acupuncture may be more effective in preventing and reducing xerostomia when administered early during CRT, rather than after chronic xerostomia has already set in. Yet, oncologists have concerns about the potentially higher risk of complications, such as infection, associated with acupuncture, especially if administered concurrently with chemoradiotherapy. Therefore, this study aims to conduct this randomised trial to evaluate the impact of early versus delayed acupuncture on patient-reported and objective measures of xerostomia, as well as the safety and tolerability of acupuncture in this setting.\n\nTo our knowledge, this will be the first randomised clinical trial evaluating the optimal timing for incorporating acupuncture to reduce xerostomia in patients undergoing chemoradiation for head and neck cancers. It is also the first study conducted in Singapore to study the role of acupuncture in reducing CRT-induced xerostomia.",[160,161,162,163,164,165],"Xerostomia","Head Cancer","Neck Cancer","Nasopharyngeal Carcinoma (NPC)","Oral Cavity Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma",[167],"Acupuncture","2026-06-24",{"date":46,"type":49},{"date":171,"type":20},"2026-06",{"date":173,"type":20},"2029-06",{"name":55,"class":56},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},"100485822","a-novel-limb-cryocompression-system-for-prevention-of-chemotherapy-induced-peripheral-neuropathy---expansion-study-100485822","NCT05606068","A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy - Expansion Study","Inclusion Criteria:\n\n* Age 21- 80 years.\n* Signed informed consent from patient or legal representative\n* Scheduled to receive weekly paclitaxel chemotherapy\n* Patients may receive other chemotherapy drugs alongside taxane e.g. Platinum\u002FHerceptin.\n\nExclusion Criteria:\n\n* Open skin wound or ulcers of the limbs\n* History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes\n* Pregnant woman\n* A score of more than 5 in Total Neuropathy Score (TNS) at baseline for cancer patients","80 Years",{"count":183,"type":20},200,[23],"The study conducted on cancer patients is designed to test safety and efficacy of limb hypothermia in cancer patients using the new Paxman Limb Cryocompression System (PLCS). Ultimately this will lead to the development of a therapy regime that will help to prevent chemotherapy-induced neuropathy in cancer patients.",[187],"Chemotherapy-induced Peripheral Neuropathy",[187,189],"Cryocompression","2026-06-17",{"date":192,"type":49},"2026-06-22",{"date":194,"type":49},"2022-11-11",{"date":196,"type":20},"2026-11",{"name":55,"class":56},2,{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":209,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},"100475637","phase-3-doxycycline-host-directed-therapy-to-improve-lung-function-and-decrease-tissue-destruction-in-pulmonary-tuberculosis-100475637","NCT05473520","Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis","Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis: A Phase III Randomized Control Trial (Doxy-TB)","Doxy-TB","The recruitment target would be 150 patients, with 75 in each arm\n\nInclusion criteria: Patients should meet all criteria:\n\n1. Aged 21 years and above\n2. Patients receiving ≤ 14 days of TB treatment or about to start standard combination TB treatment\n3. Confirmed pulmonary TB with positive acid-fast bacilli smear and\u002For positive nucleic acid amplification test (NAAT) and\u002For TB culture results\n4. CXR demonstrating pulmonary involvement with cavity or cavities\n5. Able to provide informed consent\n\nExclusion criteria:\n\n1. HIV co-infection\n2. Previous pulmonary TB\n3. Severe, pre-existing lung disease such as pulmonary fibrosis, bronchiectasis, COPD and lung cancer\n4. Pregnant or breast feeding\n5. Allergies to tetracyclines\n6. Patients on retinoic acid, neuromuscular blocking agents and pimozide which may increase risk of drug toxicity\n7. Autoimmune disease and\u002For on systemic immunosuppressants\n8. Use of any investigational or non-registered drug, vaccine or medical device other than the study drug within 182 days preceding dosing of study drug, or planned use during the study period\n9. Enrolment in any other clinical trial involving a systemic drug or intervention involving the lung\n10. Evidence of severe depression, schizophrenia or mania\n11. ALT \\> 3 times upper limit of normal\n12. Creatinine \\> 2 times upper limit of normal\n13. Principal investigator assessment of lack of willingness to participate and comply with all requirements including follow-up of the protocol, or identification of any factor felt to significantly increase the participant's risk of suffering an adverse outcome",{"count":208,"type":20},150,[210],"PHASE3","Tuberculosis (TB) is a global pandemic that despite successful treatment and bacterial eradication can cause chronic ill health, such as pulmonary impairment after tuberculosis (PIAT) and cardiovascular disease (CVD). A recent Phase 2b double-blind randomised-controlled clinical trial shows that adjunctive doxycycline therapy is safe, accelerates resolution of inflammation, suppresses tissue damaging enzyme activity and decreases pulmonary cavity volume (1). We aim to determine if adjunctive doxycycline can reduce PIAT and improve cardiovascular outcomes in a fully powered Phase III trial of 8 weeks of adjunctive doxycycline alongside standard pulmonary TB (PTB) treatment.\n\nThe investigators hypothesize that doxycycline inhibits tissue destruction in patients with PTB and thereby leads to improved lung function after treatment.\n\nSpecific aims\n\n1. To assess improvement in lung function as measured by forced expiratory volume (FEV1) predicted in PTB patients given doxycycline versus placebo.\n2. To investigate whether doxycycline will hasten the resolution of pulmonary cavities measured by CT thorax\n3. To investigate whether doxycycline can suppress inflammatory markers including matrix metalloproteinases\n4. To investigate whether doxycycline can accelerate time to sputum conversion\n5. To evaluate the effect of doxycycline on cardiovascular outcomes such as the incidence of acute coronary syndrome (ACS) and pulmonary hypertension\n6. To investigate whether doxycycline improves TB drug concentrations in sputum and plasma.\n7. To assess the safety profile of doxycycline with concurrent standard anti-tuberculous treatment.",[213,214,215],"Tuberculosis","Acute Coronary Syndrome","Pulmonary Hypertension (Diagnosis)","2026-06-08",{"date":218,"type":49},"2026-06-09",{"date":220,"type":49},"2023-05-24",{"date":222,"type":20},"2030-01-31",{"name":55,"class":56},6,{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":247,"locationsCount":224},"100550374","phase-2-adjunctive-doxycycline-for-central-nervous-system-tuberculosis-100550374","NCT06446245","Adjunctive Doxycycline for Central Nervous System Tuberculosis","DIRECT: Doxycycline Adjunctive Therapy to Reduce Excess Mortality and Complications From Central Nervous System Tuberculosis - Phase II Randomized Clinical Trial","DIRECT","Inclusion Criteria:\n\n1. Aged 21 years and above.\n2. Patients receiving ≤ 7 days of TB treatment or about to start combination TB treatment, including injectable agents, where required.\n3. Patients with clinical evidence of TB meningitis, as per established diagnostic criteria, defined as either definite, probable or possible CNS-TB:\n\n   1. \"Definite\" CNS-TB would be defined if acid-fast bacilli (AFB) or a positive nucleic acid amplification test for M. tuberculosis in the cerebrospinal fluid of patients.\n   2. \"Probable\" CNS-TB would be defined if the patient exhibit one or more of the following: suspected pulmonary tuberculosis on chest radiography, acid-fast bacilli found in any specimen other than the cerebrospinal fluid or clinical evidence of other extrapulmonary tuberculosis.\n   3. \"Possible\" CNS-TB would be defined if the patients exhibit at least four of the following: a history of tuberculosis, predominance of lymphocytes in the cerebrospinal fluid, a duration of illness of more than five days, a ratio of cerebrospinal fluid glucose to plasma glucose of less than 0.5, altered consciousness, yellow cerebrospinal fluid, or focal neurologic signs.\n4. Alanine aminotransferase (ALT) level \\\u003C 3 times the upper limit of normal.\n5. Able to provide informed consent. If the patient has no mental capacity to give consent, then consent may be provided for by the patient's next of kin.\n6. Lumbar puncture and brain imaging (either computed tomography or magnetic resonance imaging, with or without contrast) is required at baseline for enrolment\n\nExclusion Criteria:\n\n1. Active Cancer\n2. Pregnant or breastfeeding\n3. Allergies to tetracyclines\n4. Patients on retinoic acid, neuromuscular blocking agents or pimozide which may increase the risk of drug toxicity.\n5. Autoimmune disease and\u002For on systemic immunosuppressants.\n6. Use of any investigational or non-registered drug, vaccine or medical device other than the study drug within 182 days preceding dosing of the study drug or planned use during the study period.\n7. Enrolment in any other clinical trial involving a systemic drug or intervention involving the CNS.\n8. Contraindications to the use of steroids.\n9. Investigators' assessment of lack of willingness to participate and comply with all requirements including follow-up of the protocol or identification of any factor presumed to significantly increase the participant's risk of suffering an adverse outcome.",{"count":183,"type":20},[127],"Although tuberculosis is now considered a treatable disease, central nervous system tuberculosis (CNS-TB) when managed with the current standard-of-care (SOC), still has mortality rates ranging from 30-50% even in tertiary hospital centers. At present, the SOC for the management of CNS-TB is anti-tuberculous therapy with adjunctive corticosteroids. In CNS-TB, the activity of pathogenic host matrix metalloproteinases (MMPs) is unopposed to tissue inhibitors of metalloproteinases (TIMPs), resulting in a matrix-degrading phenotype which may drive worse outcomes in CNS-TB. In a prior established CNS-TB murine model, the investigators have demonstrated that adjunctive MMP inhibition using doxycycline, a widely available and cheap drug, in addition to standard TB treatment, compared with standard TB treatment alone, improved murine survival (Manuscript in preparation). The investigators previously showed that in humans with pulmonary TB, doxycycline with anti-TB treatment is safe, accelerates the resolution of inflammation, and suppresses systemic and respiratory MMPs. Hence, the investigators are now ideally positioned to determine if adjunctive doxycycline in patients with CNS-TB can improve clinical outcomes. The investigators will perform a Phase 2 double-blind randomized-controlled trial (RCT) of adjunctive doxycycline versus placebo with standard TB treatment and steroids for 8 weeks, with the primary outcome of 8-week mortality or severe neurological deficits.",[237,238,239,240],"Tuberculosis, Meningeal","Tuberculosis; Meningitis (Etiology)","Tuberculosis, Central Nervous System","Tuberculosis; Meningoencephalitis (Etiology)","2026-05-28",{"date":243,"type":49},"2026-06-01",{"date":245,"type":49},"2025-08-21",{"date":85,"type":20},{"name":55,"class":56},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":16,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":21,"phases":259,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":87},"100640963","combined-tms-tscs-for-lower-limb-rehabilitation-in-chronic-incomplete-sci-100640963","NCT07595497","Combined TMS-tSCS for Lower Limb Rehabilitation in Chronic Incomplete SCI","A Randomized Controlled Trial Comparing Combined TMS-tSCS Neuromodulation Versus tSCS Alone Lower Limb Rehabilitation in Chronic Incomplete SCI","Inclusion Criteria\n\n* Age 18-65 years at enrolment\n* Chronic traumatic spinal cord injury, defined as ≥12 months post-injury\n* Incomplete spinal cord injury, AIS grade C or D\n* Neurological level of injury from C2 to L1\n* Baseline Lower Extremity Motor Score (LEMS) \\>10 points\n* Medically stable\n* Able to provide informed consent\n* Able to commit to the full study duration\n* Able to attempt the 10-Meter Walk Test and 6-Minute Walk Test, with or - without assistive devices and standby assistance\n\nExclusion Criteria\n\n* History of seizures or epilepsy\n* Implanted electronic devices, such as: Pacemaker, Cochlear implant, Deep brain stimulator, Spinal cord stimulator, Metallic implants in the head or spine\n* Pregnancy or planned pregnancy\n* Active psychiatric disorder or cognitive impairment\n* Concomitant neurological conditions, such as: Stroke, Traumatic brain injury and Neuropathy\n* Skin breakdown at electrode sites\n* Current participation in another clinical trial\n* History of skull surgery or craniotomy\n* Use of medications that alter cortical excitability within the past 2 weeks","18 Years","65 Years",{"count":258,"type":20},24,[23],"he goal of this clinical trial is to learn if combined brain and spinal cord stimulation using TMS-tSCS can improve leg strength and walking recovery in adults with chronic incomplete spinal cord injury.\n\nThe main questions it aims to answer are:\n\nDoes combined TMS-tSCS improve lower limb motor function more than tSCS alone? Is combined TMS-tSCS safe and does it improve walking speed, independence, muscle activity, spasticity, and nerve pathway function?\n\nResearchers will compare combined TMS-tSCS with tSCS alone with sham TMS to see if adding brain stimulation leads to better recovery than spinal stimulation alone.\n\nParticipants will:\n\nAttend 32 treatment sessions over 16 weeks. Receive either combined TMS-tSCS or tSCS with sham TMS. Undergo assessments of leg strength, walking speed, daily function, muscle stiffness, muscle activity, and nerve pathway function before and after treatment.",[262],"Spinal Cord Injuries (SCI)",[264,265,266,267,268,269],"lower extremity motor score","motor rehabilitation","Neuromodulation","spinal cord injury","Transcranial Magnetic Stimulation","transcutaneous spinal cord stimulation","2026-05-12",{"date":272,"type":49},"2026-05-19",{"date":274,"type":20},"2027-01-01",{"date":276,"type":20},"2028-03-01",{"name":55,"class":56},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":256,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":286,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":87},"100638828","combined-rtms-and-tscs-for-upper-limb-recovery-in-cervical-sci-100638828","NCT07586644","Combined rTMS and tSCS for Upper Limb Recovery in Cervical SCI","Combined Repetitive Transcranial Magnetic Stimulation and Transcutaneous Spinal Cord Stimulation for Upper Limb Recovery in Chronic Incomplete Cervical Spinal Cord Injury: Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Chronicity: More than 12 months post-injury at enrollment\n* Injury type: Traumatic or non-traumatic incomplete cervical SCI, neurological level C2 to C8\n* AIS classification: Grade C or D\n* UEMS: 10 to 20 out of 25 on the more impaired side; lower bound 10 ensures sufficient voluntary activation for task training and elicitable MEPs, upper bound avoids ceiling effects.\n* Grip strength: MMT grade 3 or higher in finger flexors (C8 myotome) on at least one side.\n* Hand function: Able to transfer at least 1 block across the partition within 60 seconds on the more impaired side.\n* Sitting tolerance: Able to tolerate upright seated posture in own wheelchair for at least 1 continuous hour without symptomatic orthostatic hypotension or pressure-related discomfort requiring position change.\n* Medical stability: No acute medical complications\n* Informed consent: Able to provide written informed consent and comply with the study schedule\n* Medications: Stable regimen for 4 weeks prior, AND participant plus clinician agreement that dosage (baclofen, tizanidine, botulinum toxin) remains unchanged throughout the 12-week intervention; any change logged as protocol deviation\n* Surgical clearance: Cleared by neurosurgeon or orthopedic surgeon for participation in tSCS-based rehabilitation\n\nExclusion Criteria:\n\n* Seizure history: History of seizures or epilepsy\n* Implanted devices: Intracranial metallic implants, cochlear implants, cardiac pacemakers, or other implanted electronic devices. Cervical spinal instrumentation (e.g., posterior rods, plates, or screws at C2 to T1) is not an exclusion for tSCS provided overlying skin is intact; participants with hardware directly beneath planned electrode sites will undergo low-intensity test stimulation during screening, and electrode placement will be shifted by one interspace if current distortion, focal discomfort, or unexpected motor thresholds are observed. Intracranial hardware remains an absolute exclusion for iTBS.\n* Prior craniotomy: Prior neurosurgical procedure involving craniotomy\n* Pregnancy: Currently pregnant or intending to become pregnant during the study period\n* Psychiatric or cognitive: Active psychiatric illness (eg, untreated major depression, psychosis) or cognitive impairment precluding informed consent\n* Concurrent neurological disease: Progressive or degenerative neurological condition (eg, multiple sclerosis, motor neuron disease)\n* Concurrent trials: Participation in another interventional rehabilitation or neurostimulation trial\n* Skin integrity: Skin lesions or breakdown at electrode placement sites (scalp or posterior cervical spine)\n* Cortical excitability medications: Medications known to alter cortical excitability (eg, antiepileptic drugs, high-dose benzodiazepines) that cannot be stabilized for at least 2 weeks prior to enrollment\n* Severe spasticity: Modified Tardieu Scale muscle reaction grade 4 (unfatigable clonus \\>10 s) at elbow or wrist flexors on the more impaired side, or spasticity judged by the treating physician as unresponsive to optimised pharmacological management.",{"count":258,"type":20},[23],"This clinical trial investigates whether combining cortical and spinal neuromodulation can improve upper limb motor recovery in adults with chronic incomplete cervical spinal cord injury (SCI). Restoring upper limb function is the top rehabilitation priority for individuals with tetraplegia, yet effective interventions remain limited.\n\nThe study combines transcutaneous spinal cord stimulation (tSCS), which enhances spinal circuit excitability, with intermittent theta burst stimulation (iTBS), a form of repetitive transcranial magnetic stimulation that increases cortical excitability and strengthens descending motor pathways. While each approach has shown independent promise, their combined use has not been evaluated in a controlled trial.\n\nEligible participants are adults aged 21-65 with chronic (\\>12 months post-injury) incomplete cervical SCI (ASIA Impairment Scale grade C or D, levels C2-C8). A total of 24 participants will be randomised 1:1 to either combined iTBS and tSCS plus standardised upper limb rehabilitation, or tSCS plus rehabilitation alone, across 24 sessions over 12 weeks.\n\nThe primary outcome is change in Upper Extremity Motor Score from baseline to week 12. Secondary outcomes cover functional performance, independence, spasticity, corticospinal excitability, quality of life, and goal attainment. Assessments occur at baseline, post-intervention, and at 4- and 12-week follow-up.\n\nAs a pilot randomised controlled trial, this study will generate the first controlled evidence on adjunctive cortical neuromodulation alongside tSCS-based rehabilitation, while also producing feasibility data to inform the design of a future definitive multicentre trial.",[262],[269,290,291,292,293,294,295,296],"intermittent theta burst stimulation","repetitive transcranial magnetic stimulation","cervical spinal cord injury","upper limb rehabilitation","neuromodulation","convergent neuromodulation","tetraplegia","2026-05-08",{"date":299,"type":49},"2026-05-14",{"date":301,"type":20},"2027-03-30",{"date":303,"type":20},"2028-12-30",{"name":55,"class":56},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":21,"phases":315,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":87},"100636415","phase-2-evaluating-ivonescimab-in-pd-1-resistant-recurrent-or-metastatic-nasopharyngeal-carcinoma-100636415","NCT07565389","Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","Phase II Open-label Study Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","AK112","Inclusion Criteria:\n\n* Participant is eligible to be included in the study only if all the following criteria are met:\n\n  1. The participant (or legally acceptable representative if applicable) provides written consent for the trial.\n  2. Participant is at least 21 years of age on the day of signing informed consent\n  3. Has a locally or centrally determined histologically or cytologically confirmed diagnosis of Epstein Barr Virus (EBV)-positive nasopharyngeal carcinoma Note: The EBV status is to be determined by the EBV-encoded small RNA in situ hybridization (EBER in situ hybridization \\[ISH\\]) assay. If EBV-positive status has been previously determined by EBER ISH assay, then no re-testing is required. If EBV status by EBER ISH assay has not been previously determined, tumour tissue from archival tissue may be submitted for EBV determination.\n  4. Has recurrent or metastatic (R\u002FM) disease not amenable to curative local therapy (surgery or radiation)\n  5. Must have seen at least 1 prior line of systemic treatment and has progressed on prior platinum-based chemotherapy and anti-PD1 therapy in the R\u002FM setting OR Progressed within 6 months of previous multimodal therapy containing platinum-based chemotherapy and anti-PD1 therapy in the locally advanced setting.\n  6. Has measurable disease based on iRECIST.\n  7. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n  8. Has an adequate organ function as defined in the following table (table 1). Specimens must be collected within 10 days prior to the start of study treatment\n  9. Willing to provide blood and tumour tissue samples (newly obtained biopsy if clinically feasible or archival specimen) to support exploratory biomarker analysis.\n\nExclusion Criteria:\n\n* Participant is excluded from the study if ANY of the following criteria apply:\n\n  1. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to first dose of study treatment.\n  2. Has prior anti-angiogenic therapy in the R\u002FM setting or within 6 months as part of multimodality therapy in the locally advanced setting. \\[Applies to cohort A only\\]\n  3. Has tumour that encases major arteries which in the opinion of the investigator carries high risk of vessel wall dehiscence.\n  4. Has a condition requiring systemic steroid therapy (\\> 10 mg daily prednisone equivalents) or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment.\n\n     Note: Inhaled or topical steroids and adrenal replacement doses \\\u003C10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted if \\\u003C or = 10 mg\u002Fday prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted.\n  5. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n\n     Note: Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a form of systemic treatment.\n  6. Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n  7. Has hypersensitivity to ivonescimab or any of its components.\n  8. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n     Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, transitional cell carcinoma of urothelial cancer, or carcinoma in situ (e.g. breast or cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded.\n  9. Has an active infection requiring systemic therapy, or serious non-healing wound, ulcer or bone fracture.\n  10. Uncontrolled hypertension (failure of diastolic blood pressure to fall below 90 mmHg, despite the use of ≥ 3 anti-hypertensive drugs or systolic blood pressure greater than 150 mmHg).\n  11. Recent cardiovascular thromboembolic event, such as the following:\n\n      1. Cardiac chest pain, defined as moderate pain that limits instrumental activities of daily living, ≤ 4 weeks before enrolment\n      2. Symptomatic pulmonary embolism ≤ 4 weeks before enrolment\n      3. Any history of acute myocardial infarction ≤ 6 months before enrolment\n      4. Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV (Appendix 4) ≤ 6 months before enrolment\n      5. Any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before enrolment\n      6. Any history of cerebrovascular accident ≤ 6 months before enrolment\n  12. Persistent proteinuria of NCI-CTCAE Grade 3 or higher (\\> 3.5 g\u002F24 hours, measured by urine protein\u002Fcreatinine ratio on a random urine sample).\n  13. Clinically significant bleeding (NCI-CTCAE Grade 3 or higher) within 30 days prior to start of study medication.\n  14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n  15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n  16. Is pregnant, breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.\n  17. A woman of childbearing potential (WOCBP) who has a positive urine pregnancy test within 72 hours prior to randomization\u002Fallocation (see Appendix 3). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n      Note: If 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative for subject to start receiving study medication.\n  18. Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required unless mandated by local health authority.\n  19. Known active Hepatitis B (defined as hepatitis B viral load detected) or Hepatitis C virus (defined as HCV RNA \\[qualitative\\] detected) infection. Patients on anti-virals but with undetectable Hepatitis B or C viral loads are not excluded.\n\n      Note: No testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.\n  20. History of having received a live virus vaccination (e.g., yellow fever, MMR, nasal flu, chicken pox or Zostavax) within 4 weeks prior to the first dose of trial treatment. Note: Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines and are not allowed.",{"count":314,"type":20},42,[127],"This study is designed as a single-arm, open-label, phase II trial to evaluate the efficacy and safety of ivonescimab in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have progressed on prior an immune checkpoint inhibitor and platinum-based chemotherapy.",[163],[319],"Ivonescimab","2026-04-27",{"date":322,"type":49},"2026-05-04",{"date":324,"type":20},"2026-05",{"date":326,"type":20},"2031-05",{"name":55,"class":56},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":337,"phases":4,"briefSummary":338,"conditions":339,"keywords":349,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":87},"100634157","potential-of-interface-care-models-to-deliver-more-appropriate-care-to-patients-with-acute-medical-illness-100634157","NCT07536035","Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness","Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness in Singapore and Decrease Utilisation of Acute Care Bed-days","Inclusion Criteria:\n\n* AMU inclusion criteria - admission from ED to AMU directly\n* Control group inclusion criteria - admission from ED to GW directly\n* Acute medical illnesses that includes infection-related conditions, falls-disequilibrium, and acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).\n\nExclusion Criteria:\n\n* Below 21 years old\n* Patients undergoing active chemotherapy\n* Patients with active pregnancy\n* Patients admitted less than 24 hours\n* Cerebrovascular disease requiring thrombolysis or intravascular intervention",{"count":336,"type":20},220,"OBSERVATIONAL","Every country in the world is experiencing growth in both the size and the proportion of older persons. As a result of the changes, the profile and needs of people with medical illnesses have evolved. How care is delivered to patients has to keep pace with these changes, or patients will experience poor care at high cost and not have their needs met. A new model of care has emerged to meet these challenges: Acute Medical Unit. Despite considerable investment and popularity of this model, questions remain: (i) Who benefits most from this care model? (ii) How may these models be most effectively implemented for the best results? (iii) How effective are these models? Singapore is well-placed to answer these questions with its national healthcare system and excellent research institutions. The investigators plan to study how effective the model is by comparing patients with similar profiles exposed to both these care models compared to how hospital care is usually provided, looking for four differences: (i) how long patients stay in hospital, (ii) how often they use the emergency department (iii) quality of health (iv) cost. Additionally, the investigators seek to characterise patterns of health needs for this group of patients.",[340,341,342,343,344,345,346,347,348],"Falls Injury","Falls","Hospitalization in Acute Care","Chronic Obstructive Pulmonary Disease (COPD)","Infection","Acute Exacerbation of Asthma","Pneumonia","UTI - Urinary Tract Infection","URTI - Viral Upper Respiratory Tract Infection",[350,351,352,353,354,355,356],"Acute Medical Unit","Acute Medicine","Interface Care","Clinical effectiveness","Cost effectiveness","prospective observational","matched controlled","2026-04-10",{"date":359,"type":49},"2026-04-17",{"date":361,"type":49},"2024-09-30",{"date":363,"type":20},"2026-05-31",{"name":55,"class":56},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":64,"sex":16,"minAge":372,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":337,"phases":4,"briefSummary":375,"conditions":376,"keywords":380,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":87},"100633353","implementation-of-decade-of-healthy-ageing-action-plan-to-screen-and-prevent-decline-in-intrinsic-capacity-in-elders-spice-through-multisectoral-collaboration-in-singapore-100633353","NCT07525583","Implementation of Decade of Healthy Ageing Action Plan to Screen and Prevent Decline in Intrinsic Capacity in Elders (SPICE) Through Multisectoral Collaboration in Singapore","SPICE","Inclusion Criteria:\n\n* pre-frail or robust older adults who can provide consent and follow instructions\n\nExclusion Criteria:\n\n* frail or with terminal illness","60 Years",{"count":374,"type":20},2500,"This study evaluates the implementation of a structured community-based pathway to screen, risk stratify, and prevent decline in intrinsic capacity (IC) among adults aged 60 years and above in Singapore. Using the World Health Organization (WHO) Integrated Care for Older People (ICOPE) framework and digital screening tools, participants will undergo IC domain screening in community settings. Individuals identified with early decline will receive targeted multidomain interventions and\u002For referral to primary or specialist care as indicated. Participants will be followed longitudinally to assess feasibility, uptake, functional trajectories, and implementation outcomes.",[377,378,379],"Frailty","Intrinsic Capacity","Lifestyle",[381,382,383,384],"intrinsic capacity","personalized intervention","frailty","geroscience",{"date":386,"type":49},"2026-04-13",{"date":388,"type":49},"2025-04-01",{"date":390,"type":20},"2027-09-30",{"name":55,"class":56},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":16,"minAge":398,"maxAge":181,"enrollmentInfo":399,"targetDuration":4,"studyType":21,"phases":401,"briefSummary":402,"conditions":403,"keywords":405,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":87},"100617519","phase-1-antigen-targeted-t-cell-therapy-for-relapsedrefractory-b-cell-lymphomas-100617519","NCT07319676","Antigen Targeted T Cell Therapy for Relapsed\u002FRefractory B Cell Lymphomas","Inclusion Criteria\n\n* Age 10 to 80 years at screening\n* PET-CT measurable disease by Lugano classification (Deauville score of ≥4) and\n* Tissue biopsy of any tumour site and flow cytometry study of CD19 and CD22 expression.\n* Relapsed B-cell lymphoma after one line of systemic therapy or autologous bone marrow transplant. This includes DLBCL, PMBCL, HGBCL, DLBCL arising from indolent lymphoma, Burkitt's lymphoma\u002Fleukemia, Mantle cell lymphoma.\n* High risk B-cell lymphoma (BCL). High risk BCL is defined by any of the criteria below:\n\n  * High-risk genetics - double\u002Ftriple hit or p53mut or deletion.\n  * IPI score ≥ 3\n  * Richter's transformation from chronic lymphocytic leukaemia.\n  * Disease refractory to treatment - PET-CT positive disease after 2 courses of rituximab-containing chemoimmunotherapy.\n* PBMC product available\n* Karnofsky or Lansky score \\>70. Or ECOG 0-2\n* Patient expected survival is more than 3 months to allow for manufacture and release of CAR T-cells.\n\nExclusion Criteria\n\n* Patients who test positive on urine or blood pregnancy testing and are pregnant or are lactating.\n* Participant of reproducible age who refuse the use of the following birth control methods if engaging in sexual activity that could lead to pregnancy. The methods include condoms, diaphragm, intrauterine device, hormonal based contraception.\n* Concomitant genetic syndromes associated with BM failure states, such as Fanconi anaemia, Kostmann syndrome, Schwachman syndrome, or any other BM failure syndrome with the exception of Down syndrome.\n* Active hepatitis B or hepatitis C within 3 months of screening.\n* Active HIV infection within 3 months of screening.\n* Grade 2 to 4 graft-vs-host disease (GVHD).\n* Received an investigational medicinal product within 1 month of screening.\n* If the total sum of CD19 and CD22 antigens expressed is less than 95.0%, patients will not be eligible. If subsequent immunophenotying of the patient's sample confirms that total sum of CD19 and CD22 antigens ≥ 95%, the patient may be rescreened.\n* Central nervous system: Uncontrolled seizures or status epilepticus; decreased conscious state (any cause)\n* Foreign patients who cannot commit to agreeable to stay in Singapore for at least 3 months post CAR T infusion and are committed to the long term monitoring post CAR T at home and in Singapore.\n* Prior treatment with any CAR T cell therapy (approved or investigational)","10 Years",{"count":400,"type":20},30,[126,127],"This is a single center, open label, phase 1 lead in to determine Recommended Phase 2 Dose (RP2D), followed by a phase 2 trial to evaluate the safety and efficacy of Epo-R-CD19 CAR T with or without CD22 CAR T-cells infused into patients with B cell lymphoma.\n\nThe study will have the following parts:\n\n* Screening\n* Pre-infusion (cell product preparation and bridging) and infusion (lymphodepletion)\n* Primary efficacy endpoints\n* Long term follow up\n\nPatients who have high risk B cell lymphoma or relapsed\u002Frefractory B cell lymphoma who fufil the trial inclusion and exclusion criteria will undergo leukapheresis following trial enrollment.\n\nCAR T-cell products will then be manufactured according to the antigen expression on the patient's biopsied tumor cells. These cells will then undergo stringent testing before the patient undergoes lymphodepletion followed by CART infusion. These patients will be admitted for the infusion and closely monitored for any CRS or ICANS.\n\nThis study will have a Phase 1 safety run in for the first 3-6 patients who receive the Epo-R-CD19 CAR T (with or without epoetin (erythropoietin)) to determine the tolerability and safety of this product. For the first 3-6 patients, if there are any DLT seen by Day 28, a data safety monitoring committee will be convened to assess the trial. Staggered dosing will be implemented for the first 2 participants in every dose level (DL1, DL2 and DL-1).\n\nFor Phase 2, the RP2D will depend on DLT. If there is no DLT at DL+1 and DL+2, then the investigators will proceed with DL+2 as the RP2D dose. On the other hand, if there is DLT despite DL-1, then the study will be redesigned. Phase 2 will continue until a total of 20 patients received their CAR T-cell infusions.\n\nCAR-T monitoring will be performed at Day 0, 7, 14, 21, 28, month 2, 3, 4, 5, 6, 12 and yearly thereafter. The total duration of the study is 15 years from CAR T infusion.",[404],"B-cell Lymphoma Refractory",[406,407,408],"Antigen targeted","T cell therapy","Relapsed\u002FRefractory B cell lymphomas","2026-04-05",{"date":411,"type":49},"2026-04-09",{"date":413,"type":49},"2026-03-02",{"date":415,"type":20},"2040-10-31",{"name":55,"class":56},{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":425,"enrollmentInfo":426,"targetDuration":4,"studyType":21,"phases":428,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":444,"locationsCount":87},"100524345","reducing-delirium-after-cabg-surgery-with-early-activation-and-sleep-promoting-routines-100524345","NCT06107517","Reducing Delirium After CABG Surgery With Early Activation and Sleep-Promoting Routines","DREAMS-OT Trial: Delirium Reduction Through Early Activation in Motivating and Sleep Promoting Routines: A Randomized Controlled Trial of Occupational Therapy for ICU Patients After Coronary Artery Bypass Graft (CABG) Surgery","DREAMS-OT","Inclusion Criteria:\n\n* Patients deemed medically suitable for elective CABG surgery\n* Patients aged 21 years and above\n* Patients who are English or Mandarin speaking.\n* Patients who are able to provide consent\n\nExclusion Criteria:\n\n* Patients who speak other languages are excluded due to the language requirements of certain outcome measures.\n* Patients with premorbid severe hearing impairment, severe cognitive impairment, progressive neurological disorders and psychological disorders will be excluded.\n* Patients with surgical complications resulting in profuse bleeding from any invasive sites, septic shock unresponsive to maximal treatment, and those who are moribund or have an expected mortality within 48 hours will be excluded.\n* Pregnant women will also be excluded from the study as well.\n* Patients who develop delirium before initiation of the treatment are also excluded from the study.","99 Years",{"count":427,"type":20},300,[23],"The goal of this randomized-controlled trial (RCT) is to compare the effectiveness of the DREAMS-OT intervention with standard care in reducing post-Coronary Artery Bypass Graft (CABG) surgery delirium in patients undergoing CABG surgery.\n\nThe aims of the study are:\n\n1. To determine if early and intensive OT will lower the incidence of post-op delirium in CABG patients compared to standard are.\n2. To determine the cost effectiveness of the DREAMS-OT intervention.\n\nThe study team will compare intervention group and standard care group (control group) to see if there is a reduction in the incidence of delirium in patients 5 days post-CABG.",[431],"Delirium, Postoperative",[433,434,435,436,437],"Delirium","Coronary Artery Bypass Grafting","Occupational Therapy","Intensive Care Units","Randomized Controlled Trial","2026-03-24",{"date":440,"type":49},"2026-03-30",{"date":442,"type":49},"2024-01-08",{"date":144,"type":20},{"name":55,"class":56},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":16,"minAge":453,"maxAge":425,"enrollmentInfo":454,"targetDuration":4,"studyType":21,"phases":456,"briefSummary":457,"conditions":458,"keywords":461,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":87},"100628351","mandibular-advancement-to-reduce-ventricular-load-and-improve-quality-of-life-in-heart-failure-100628351","NCT07460505","Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure","Mandibular Advancement to Reduce Ventricular Load and Improve Quality of Life in Heart Failure - a Randomized Controlled Trial","MARVEL-HF","Inclusion Criteria:\n\n* Age of at least 40 years old with the capacity to provide signed, written informed consent\n* Ischemic or non-ischemic cardiomyopathy with a left ventricular ejection fraction of 20% to 40% in the previous 6 months\n* Stable chronic HF with NYHA functional class I-III symptoms on maximally tolerated background therapy for at least 4 weeks\n* NT-proBNP \\>600 pg\u002FmL (for participants in sinus rhythm) or \\>900 pg\u002FmL (for participants in atrial fibrillation) in the previous 6 months (same as leading HF trials)\n* Agree to follow the study protocol\n* Able and willing to undergo a hospital-based overnight polysomnography\n\nExclusion Criteria:\n\n* Known OSA and already on regular treatment\n* Moderate or severe valvular stenosis or regurgitation\n* Severe hypoxemia on polysomnography ODI \\>60 or min SpO2 \\\u003C60%\n* Specific HF etiologies, including hypertrophic cardiomyopathy with left ventricular outflow tract obstruction; pericardial disease; infiltrative or inflammatory myocardial disease; valvular heart disease with severe aortic or primary mitral regurgitation, moderate or severe aortic stenosis, any mitral stenosis requiring surgical repair, or active endocarditis\n* Contraindications to MAD: less than six teeth in each arch; inability to advance the mandible and open the jaw widely.\n* Pre-existing temporomandibular joint problems, severe bruxism, and advanced periodontal disease (with mobility affecting MAD stability).\n* Patients who are planning to have restorations, dental prostheses or implants done in the next 12 months\n* Limited life expectancy (\\\u003C one year)\n* Cardiac or cerebrovascular events in the past 6 months, including myocardial infarction, unstable angina leading to hospitalization, uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, transient ischemic attack, carotid revascularization, endovascular procedure, or surgical intervention for peripheral vascular disease\n* Current or planned mechanical circulatory support or heart transplantation Current or planned (within the next 6 months) hemodialysis or peritoneal dialysis","40 Years",{"count":455,"type":20},328,[23],"Heart failure with reduced ejection fraction (HFrEF) is a serious condition that limits daily activities and often leads to hospital stays and early death. Many patients with HFrEF also have obstructive sleep apnea (OSA), a common but often undiagnosed condition where breathing repeatedly stops during sleep. This causes drops in oxygen, poor sleep, and stress on the heart, which can make heart failure worse.\n\nThe investigators are studying whether a device called a mandibular advancement device (MAD)-a mouthpiece worn during sleep that keeps the airway open-can help people with both HFrEF and moderate-to-severe OSA. This device is already approved to treat OSA and is often more comfortable and easier to use than a CPAP machine.\n\nIn our study, 328 patients in Singapore will be randomly assigned to use either the MAD or a sham device that looks the same but doesn't move the jaw. They will wear the device for 12 months. We will measure changes in a blood marker linked to heart failure severity, as well as exercise ability, blood pressure, sleep quality, and hospital visits.\n\nThe investigators hope this study will show that MAD is a simple and patient-friendly way to improve outcomes in people with heart failure.",[459,460],"Heart Failure","OSA - Obstructive Sleep Apnea",[462,463,464,465,466],"heart failure","OSA","clinical trial","biomarker","quality of life","2026-03-04",{"date":469,"type":49},"2026-03-10",{"date":471,"type":20},"2026-05-01",{"date":473,"type":20},"2031-04-01",{"name":55,"class":56},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":181,"enrollmentInfo":482,"targetDuration":4,"studyType":21,"phases":483,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":87},"100626412","navigated-repetitive-tms-for-chronic-tinnitus-100626412","NCT07435298","Navigated Repetitive TMS for Chronic Tinnitus","Neuronavigated Transcranial Magnetic Stimulation As An Adjunctive Treatment For Chronic Tinnitus","Inclusion Criteria:\n\n1. Age 21-80 years old;\n2. Subjective tinnitus severity as per Tinnitus-Visual Analogue Scale of 1\u002F10 and above (in any domain: sound, distress, Quality of Life)\n\nExclusion Criteria:\n\n1. Pregnancy;\n2. Any metal implants inside the body that are contraindications of MRI scan;\n3. Cardiac pacemakers;\n4. Epilepsy with recurrent seizures;\n5. Cognitively impaired patients will be excluded;\n6. Claustrophobia;\n7. Uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina;\n8. Major depression and a history of psychotic disorders;\n9. Terminal diagnosis with life expectancy \\\u003C=1 year.",{"count":156,"type":20},[23],"This study is testing whether a special type of brain stimulation called neuronavigated TMS can help reduce tinnitus (ringing in the ears). 50 people with tinnitus will each receive 20 treatment sessions - 10 real treatments and 10 sham treatments in random order, with a 2-week break between them. Before starting, participants get an MRI brain scan to guide where the stimulation device is placed. Questionnaires of measuring tinnitus severity will be asked four times throughout the study to determine to check the effect of TMS on treating tinnitus.",[486],"Tinnitus","2026-02-20",{"date":489,"type":49},"2026-02-27",{"date":491,"type":49},"2025-11-01",{"date":493,"type":20},"2027-10-30",{"name":55,"class":56},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":181,"enrollmentInfo":502,"targetDuration":4,"studyType":21,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":515,"locationsCount":87},"100626183","tscs--ul-robotics-training-in-sci-patients-100626183","NCT07432321","tSCS + UL Robotics Training in SCI Patients","A Pilot Study on the Cumulative Effects of Transcutaneous Spinal Cord Stimulation (tSCS) With Upper Limb Robotics Training in Upper Limb Rehabilitation in Patients With Tetraplegic Spinal Cord Injury","Inclusion Criteria:\n\n1. At least 6 months to 5 years from the diagnosis of the traumatic SCI;\n2. Participants between 21 and 80 years of age;\n3. C2-8 level injuries;\n4. ISNCSCI-UEMS \\>25,\n5. Pinch force \\> 25 N;\n6. Grasp force \\> 100 N;\n7. Able to perform the box and block test;\n8. Sitting tolerance for at least 1 hour (No known postural hypotension issues or pressure intolerance);\n9. Capable of providing an informed consent;\n10. Cleared by Neurosurgeons\u002FOrthopaedic Surgeon for tSCS;\n\nExclusion Criteria:\n\n1. Participant has uncontrolled cardiopulmonary disease or cardiac symptoms as determined by the investigator.\n2. Participant has any unstable or significant medical condition that is likely to interfere with study procedures or likely to confound performance and outcomes like uncontrolled neuropathic pain, depression, severe cognitive impairment.\n3. Unstable or uncontrolled autonomic dysreflexia.\n4. Requires ventilator support.\n5. Spasms that limit the ability of the subjects to participate in the study training as determined by the investigator.\n6. Has an autoimmune etiology of spinal cord dysfunction\u002Finjury\n7. History of additional neurologic disease, such as stroke, multiple sclerosis and traumatic brain Injury.\n8. Pain in shoulder and\u002For hand which will be inhibitory towards rehabilitative therapy.\n9. Severe Upper limb contractures.\n10. Acute Medical conditions to Upper limb (ie Fractures that would limit ROM and\u002For weightbearing).\n11. Participants who are pregnant.",{"count":224,"type":20},[23],"This study is aimed to evaluate whether transcutaneous spinal cord stimulation (tSCS) can augment upper limb robotic training (ULRT) to improve functional mobility in participants with chronic spinal cord injuries. It also evaluates the impact of the tSCS+ULRT on health-related quality of life (HRQOL), compared to ULRT alone.\n\nThis is a prospective single-arm crossover study in participants with incomplete chronic traumatic spinal cord injury. 6 to 8 subjects with C2-8 level injuries will be recruited. The intervention includes Phase 1 of training which consists of 16 sessions of ULRT + conventional occupational therapy in 8-10 weeks, and Phase 2 of training which consists of 16 sessions of ULRT training + tSCS + conventional occupational therapy in 8-10 weeks.\n\nOutcome measures including mobility function assessment and neuromuscular assessment will be collected at Baseline, Post-Phase 1, Post-Phase 2, and 4 weeks Follow-up. A satisfaction survey on the intervention \"ULRT training + tSCS + conventional physiotherapy\" will be performed at end of the study.",[506],"Spinal Cord Injuries",[267,269,508],"upper limb robotic training (ULRT)","2026-02-19",{"date":511,"type":49},"2026-02-25",{"date":513,"type":49},"2025-09-18",{"date":390,"type":20},{"name":55,"class":56},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":256,"enrollmentInfo":523,"targetDuration":4,"studyType":21,"phases":524,"briefSummary":525,"conditions":526,"keywords":528,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":534,"locationsCount":87},"100510033","transcutaneous-spinal-cord-stimulation-with-robotic-gait-training-in-chronic-sci-100510033","NCT05921175","Transcutaneous Spinal Cord Stimulation With Robotic Gait Training in Chronic SCI","A Pilot Study on the Cumulative Effects of Transcutaneous Spinal Cord Stimulation (tSCS) With Robotic Gait Training in Trunk Muscle Activity and Walking Index in Chronic Spinal Cord Injury","Inclusion Criteria:\n\n1. Between 6 months to 5 years from the diagnosis of the traumatic SCI and who are not walking independently;\n2. Age between 21 to 65 years old;\n3. Incomplete spinal cord injury: ASIA Impairment Scale (AIS) Grade: B-D;\n4. Spinal cord injury level: T1- L1, or C2-C8;\n5. SCI-TCT Score \\> 13;\n6. Capable of providing an informed consent;\n7. Cleared by Neurosurgeons\u002F Orthopeadic Surgeons for tSCS;\n8. Meets prerequisites for Ekso wearable robotic exoskeleton training.\n\nExclusion Criteria:\n\n1. Participant has uncontrolled cardiopulmonary disease or cardiac symptoms as determined by the investigator;\n2. Participant has any unstable or significant medical condition that is likely to interfere with study procedures or likely to confound performance and outcomes like uncontrolled neuropathic pain, depression, severe cognitive impairment;\n3. Unstable or uncontrolled autonomic dysreflexia;\n4. Requires ventilator support;\n5. Spasms that limit the ability of the subjects to participate in the study training as determined by the investigator;\n6. Skin conditions that limit the application of tSCS electrodes;\n7. Active implanted medical devices that may be affected by tSCS;\n8. Pregnant, planning to become pregnant or breastfeeding;\n9. Concurrent participation in another drug or device trial that may interfere with this study;\n10. Participated in wearable exoskeleton training within the last 3 months prior to enrolment.\n11. Peripheral nerve injury or significant Lumbar Radiculopathy",{"count":224,"type":20},[23],"This study is aimed to evaluate whether transcutaneous spinal cord stimulation (tSCS) can augment robotic gait training (RGT) to improve functional mobility in participants with chronic spinal cord injuries. It also evaluate the impact of the tSCS+RGT on health-related quality of life (HRQOL), compared to RGT alone.\n\nThis is a prospective single-arm crossover study in participants with incomplete chronic traumatic spinal cord injury. 6 subjects with paraplegia and 6 subjects with tetraplegia will be recruited. The intervention includes Phase 1 of training which consists of 16 sessions of robotic gait training (RGT) + conventional physiotherapy in 8-10 weeks, and Phase 2 of training which consists of 16 sessions of RGT training + tSCS + conventional physiotherapy in 8-10 weeks.\n\nOutcome measures including mobility function assessment and neuromuscular assessment will be collected at Baseline, Post-Phase 1 and Post-Phase 2. A satisfaction survey on the intervention \"RGT training + tSCS + conventional physiotherapy\" will be performed at week-18 assessment.",[527],"Spinal Cord Injury",[267,269,529],"robotic gait training",{"date":110,"type":49},{"date":532,"type":49},"2024-11-13",{"date":51,"type":20},{"name":55,"class":56},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":16,"minAge":543,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":21,"phases":546,"briefSummary":547,"conditions":548,"keywords":551,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":87},"100591695","cpap-vs-mad-for-osa-in-patients-with-cognitive-impairment-a-randomized-clinical-trial-100591695","NCT06983769","CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial","Cognition Recovery in Sleep Apnea Patients With Cardiovascular Risk by Evaluating Nasal CPAP Versus Dental Oral Appliance","CRESCENDO","Inclusion Criteria:\n\nAge of at least 45 Chinese, Malay, Indian Referred to the sleep clinics of the CRESCENDO participating centers for suspected OSA, underwent a clinically indicated level 1 polysomnography, and diagnosed to have moderate-to-severe OSA (AHI ≥ 15 events\u002Fhour) Mild cognitive impairment: MoCA score \\\u003C27 (for those with \\>10 years of education) and \\\u003C26 (for those with ≤10 years of education) Agree to follow the study protocol\n\nExclusion Criteria:\n\nKnown OSA and already on regular treatment Severe cognitive impairment (MoCA \\\u003C10) Severe hypoxemia on polysomnography ODI \\>60 or min SpO2 \\\u003C60% Known schizophrenia, bipolar disorder, severe depression, drug abuse or alcohol abuse Contraindications to MAD: less than six teeth in each arch; inability to advance the mandible and open the jaw widely. Pre-existing temporomandibular joint problems, severe bruxism, and advanced periodontal disease Limited life expectancy (\\\u003C one year) Cardiac or cerebrovascular events leading to hospitalization in the past three months Complex cardiovascular diseases: cyanotic congenital heart disease, moderate to severe pulmonary hypertension On regular medications that could affect the neurocognitive function and\u002For alertness","45 Years",{"count":545,"type":20},260,[23],"Obstructive sleep apnea (OSA) is a prevalent condition that significantly impacts the sleep health and overall well-being of millions of adults worldwide. It is characterized by breathing difficulties during sleep caused by an obstructed upper airway, leading to fragmented sleep, oxygen deprivation, and increased sympathetic activity. OSA and its associated health problems contribute to an annual economic burden exceeding $150 billion in the United States. Studies have shown that individuals with OSA are 26% more likely to develop cognitive impairment compared to those without the condition. However, despite the effectiveness of continuous positive airway pressure (CPAP) therapy, many patients struggle with acceptance and adherence to this treatment. As an alternative, mandibular advancement devices (MADs) have gained acceptance among OSA patients by improving upper airway anatomy through repositioning of the jaw and tongue, thus reducing collapsibility. This non-invasive approach shows promise, particularly in addressing the unique craniofacial features commonly found in East Asian OSA patients.\n\nTo further investigate the efficacy of MAD versus CPAP therapy, a multi-center, randomized clinical trial is proposed. The trial aims to evaluate cognitive function using established assessment tools and explore the relationship between different Asian ethnicities and changes in cognitive function, ambulatory blood pressure, and cerebral oxygen saturation. Additionally, brain MRI will be utilized to examine whether baseline brain structure and function can predict treatment response in OSA patients. Participants diagnosed with moderate-to-severe OSA will be randomly assigned to either the MAD or CPAP group in a 1:1 ratio. Baseline assessments, along with six-month and one-year follow-ups, will be conducted to assess the impact of the interventions. This trial seeks to provide valuable insights into the effectiveness of MAD versus CPAP therapy in Asian populations, specifically focusing on their effects on cognitive function and other relevant outcomes in individuals with OSA.",[549,550],"Obstructive Sleep Apnea (OSA)","Mild Cognitive Impairment",[552],"Sleep, Cognition, Mandibular advancement device, CPAP, Clinical trial,","2026-01-18",{"date":555,"type":49},"2026-01-21",{"date":557,"type":49},"2026-01-01",{"date":559,"type":20},"2030-12-31",{"name":55,"class":56},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":64,"sex":16,"minAge":122,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":21,"phases":571,"briefSummary":572,"conditions":573,"keywords":579,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":87},"100620522","liquid-biopsy-based-pre-screening-to-streamline-ldct-lung-cancer-screening-in-high-risk-individuals-100620522","NCT07358715","Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals","A Multimodal Liquid Biopsy-Based Assay as a Pre-Screening Test Before Low Dose CT Thorax (LDCT) to Streamline Lung Cancer Screening in High-Risk Individuals","Inclusion Criteria\n\nHigh-Risk Individuals (n = 100)\n\n* No prior history of lung cancer\n* Meets one of the following high-risk definitions:\n\n  * Current or former smoker (quit within the past 15 years), aged 55-74 years, with a smoking history of ≥30 pack-years; OR\n  * Never-smoker aged 55-75 years with a first-degree family history of lung cancer\n* Able and willing to provide written informed consent\n\nEarly-Stage Lung Cancer Patients (n = 20)\n\n* Aged ≥21 years\n* Histologically or clinically confirmed stage I-II lung cancer\n* Treatment-naïve (no prior surgery, chemotherapy, radiotherapy, or immunotherapy for lung cancer)\n* Able and willing to provide written informed consent\n\nAdvanced-Stage Lung Cancer Patients (n = 20)\n\n* Aged ≥21 years\n* Histologically or clinically confirmed stage III-IV lung cancer\n* Treatment-naïve (no prior systemic or local therapy for lung cancer)\n* Able and willing to provide written informed consent\n\nExclusion Criteria\n\nApplicable to All Participants\n\n* Pregnant or breastfeeding women\n* Inability or unwillingness to comply with study procedures\n\nHigh-Risk Individuals Only\n\n* Known allergy or contraindication to CT contrast agents\n* Prior low-dose CT (LDCT), CT thorax, or PET-CT performed within 12 months prior to enrollment\n\nLung Cancer Cohorts Only\n\n• Receipt of any prior cancer-directed treatment for lung cancer","75 Years",{"count":570,"type":20},140,[23],"This study evaluates the feasibility and cost-effectiveness of using a blood-based liquid biopsy assay as a pre-screening tool before low-dose CT (LDCT) for lung cancer screening. By identifying individuals unlikely to have lung cancer, this approach aims to reduce unnecessary LDCT scans, radiation exposure, and healthcare costs, while improving early detection, particularly among high-risk individuals including never-smokers with a family history of lung cancer.",[574,575,576,577,578],"Lung Cancer","Lung Neoplasms","Early Lung Cancer Detection","Cancer Screening","High-Risk Populations",[580,581,582,583,584,585,586,587,588,589,590],"Liquid biopsy","DNA methylation","Exosomes","Blood-based screening","Low-dose CT","LDCT","Lung cancer screening","Early cancer detection","High-risk individuals","Never-smokers","Multimodal assay","2026-01-13",{"date":593,"type":49},"2026-01-22",{"date":595,"type":49},"2024-11-01",{"date":597,"type":20},"2028-12-31",{"name":55,"class":56},{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":607,"minAge":122,"maxAge":543,"enrollmentInfo":608,"targetDuration":4,"studyType":21,"phases":610,"briefSummary":611,"conditions":612,"keywords":614,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":87},"100611487","antenatal-myo-inositol-supplementation-in-pre-existing-diabetes-100611487","NCT07241221","Antenatal Myo-inositol Supplementation in Pre-existing Diabetes","Antenatal Myo-inositol Supplementation in Pre-existing Diabetes to Promote Normal Neonatal Outcomes","AMulet","Inclusion Criteria\n\n* Pregnant women aged 21 years to 45 years old at the time of recruitment\n* Ongoing, viable, singleton intrauterine pregnancy\n* Between 12+0 days-16+6 days weeks' gestation at recruitment\n* T2DM diagnosed by a documented 75g Oral Glucose Tolerance Test (OGTT) showing a fasting glucose of \\>7 mmol\u002FL or 2h glucose \\>11.1 mmol\u002FL, or an HbA1C \\>6.5%, either prior to pregnancy or during the first 16 weeks of the index pregnancy\n* Intend to receive antenatal care and give birth at NUH\n* Willing to provide written, informed consent\n* Able to swallow capsules and comply with trial procedures\n\nExclusion Criteria\n\n* Known or suspected fetal aneuploidy or genetic\u002Fstructural anomaly\n* Severe allergy to food items requiring carriage of an Epipen at all times","FEMALE",{"count":609,"type":20},182,[23],"This feasibility pilot study aims to gather data that can guide the design of a larger, more comprehensive trial to establish the effects of myo-inositol supplementation on supporting healthy outcomes in pregnancies complicated by Type 2 Diabetes Mellitus (T2DM). It seeks to assess myo-inositol's potential to support fetal and neonatal health, and optimise maternity outcomes as a complementary approach and adjuvant to existing diabetes mellitus therapies, as well as investigate the underlying biological mechanisms.",[613],"Perinatal and Neonatal Outcomes in Pregnancies With Type 2 Diabetes Mellitus (T2DM)",[615,616,617,618,619,620,621,622,623,624,625,626],"Diabetes","Pregnancy","Myo-inositol","Folic acid","Dietary Supplement","Birthweight","Prematurity","Neonatal Intensive Care Unit Admission","Stillbirth","Neonatal Death","Neonatal Complications","Maternity Complications","2025-12-02",{"date":629,"type":49},"2025-12-09",{"date":631,"type":20},"2025-12",{"date":633,"type":20},"2029-08-31",{"name":55,"class":56},{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":16,"minAge":643,"maxAge":255,"enrollmentInfo":644,"targetDuration":4,"studyType":21,"phases":646,"briefSummary":647,"conditions":648,"keywords":651,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":661,"leadSponsor":663,"locationsCount":198},"100599952","phase-2-dupilumab-therapy-in-nephrotic-syndrome-in-children-100599952","NCT07091175","Dupilumab Therapy in Nephrotic Syndrome in Children","Singapore-Malaysian Renal Trials - Nephrotic Syndrome (SMART-NS): Dupilumab Maintenance Therapy for Steroid-dependent and Frequently Relapsing Nephrotic Syndrome","SMART-NS","Inclusion Criteria:\n\n1. Age between 6 years old and 18 years old at the point of recruitment with idiopathic nephrotic syndrome with disease onset between 1-18 years old\n2. Steroid-dependent disease or frequently relapsing disease prior to commencement of maintenance immunosuppression\n3. On oral prednisolone +\u002F- mycophenolate or levamisole only as maintenance therapy for 6 months or more, and with inadequate disease control or steroid toxicity on therapy\n4. Nephrotic relapse or partial relapse (clinical or biochemical) within the last 1 year either unprovoked or during prednisolone wean, and which responded to increase in steroids\n5. In complete remission at the time of recruitment\n6. Competent with, and compliant to, daily urine protein monitoring with Albustix\n\nExclusion Criteria:\n\n1. Pre-existing ophthalmological conditions except refractive errors, squint or mild cataract\n2. Current symptoms of helminth infection or travel to endemic areas, unless helminth infection is excluded\n3. eGFR (by Bedside Schwartz equation) \\\u003C60 ml\u002Fmin\u002F1.73m2\n4. Received Rituximab or other B-cell depleting agents within the last 1 year\n5. Biopsy proven focal segmental glomerulosclerosis\n6. Known ongoing infection including HIV, Hepatitis B, Hepatitis C or tuberculosis, otherwise immunosuppressed or with frequent infections\n7. Known or suspected non-compliance to medication or follow-up\n8. Pregnancy or intention to become pregnant\n9. Major systemic conditions, i.e. ASA Physical Status III-IV.\n10. Known hypersensitivity to dupilumab or any of its excipients","6 Years",{"count":645,"type":20},66,[127],"The goal of this clinical trial is to learn if dupilumab works to treat severe nephrotic syndrome in children. It will also learn about the safety of dupilumab.\n\nThe main questions it aims to answer are:\n\n* Does dupilumab reduce the time to relapse of nephrotic syndrome?\n* What medical problems do participants have when taking dupilumab?\n\nResearchers will compare dupilumab to a placebo (a look-alike substance that contains no drug) to see if dupilumab works to treat severe nephrotic syndrome.\n\nParticipants will:\n\n* Receive an injection of dupilumab or placebo (just under the skin) every 2 weeks (if ≥30kg) or every 4 weeks (if \\\u003C30kg) for 24 weeks (6 months)\n* Wean down their prednisolone dose after starting the injections of dupilumab or placebo\n* Visit the clinic once every 2 weeks for checkups and tests\n* Keep a nephrotic diary to record down the urine dipstick result each day, together with the dose of prednisolone taken\n\nIf protein returns in participant's urine, they will have completed the study at that point. However, if the participant is found to have received the placebo, they will be offered to receive dupilumab for up to 24 weeks.",[649,650],"Nephrotic Syndrome in Children","Nephrotic Syndrome Steroid-Dependent",[652,653,654,655,656],"Dupilumab","Steroid sensitive nephrotic syndrome","Steroid dependent nephrotic syndrome","Frequently relapsing nephrotic syndrome","Paediatric","2025-11-27",{"date":659,"type":49},"2025-12-05",{"date":657,"type":49},{"date":662,"type":20},"2028-02-28",{"name":55,"class":56},{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":669,"acronym":4,"eligibilityCriteria":670,"healthyVolunteers":12,"sex":16,"minAge":671,"maxAge":4,"enrollmentInfo":672,"targetDuration":4,"studyType":21,"phases":674,"briefSummary":675,"conditions":676,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":679,"lastUpdatePostDateStruct":680,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":87},"100611604","effectiveness-of-pulpotomy-vs-root-canal-treatment-in-extremely-deep-caries-100611604","NCT07242742","Effectiveness of Pulpotomy vs. Root Canal Treatment in Extremely Deep Caries","Effectiveness of Pulpotomy vs. Root Canal Treatment in Extremely Deep Caries: A Randomized Controlled Trial Conducted in Supervised Undergraduate Clinics","Inclusion Criteria:\n\n* Aged 12 years or older\n* Mature maxillary or mandibular permanent tooth with extremely deep restorations\u002Fcaries penetrating the entire thickness of dentine on the radiograph without a radiopaque zone separating the lesion from the pulp (Bjorndal et al., 2019)\n* Tooth may or may not be symptomatic at the time of recruitment but must be responsive to cold and EPT sensibility testing\n* Tooth is restorable and can be adequately isolated during treatment\n* One tooth per patient\n\nExclusion Criteria:\n\n* Teeth with difficult access and unpredictable isolation using a rubber dam\n* Teeth aberrant root canal morphology, extreme root curvatures (\\>30 degrees), calcified canals\u002Fsclerosed pulp\n* Teeth indicated for elective root canal treatment for restorative purposes\n* Teeth with apical periodontitis\n* Presence of apical radiolucency\n* Any evidence of purulence or excessive bleeding that cannot be controlled with a cotton pellet with 1.25% hypochlorite for 10 minutes\n* History of trauma to the tooth\n* Teeth with active periodontal disease (pocket depth \\>5mm)\n* Patients with complex medical histories that may affect their caries experience and healing ability (immunocompromised, radiotherapy etc.)\n* Patients who are pregnant or breast-feeding\n* Patients who are unable to consent","12 Years",{"count":673,"type":20},93,[23],"Recent clinical trials comparing pulpotomy versus root canal treatment (RCT) have shown promising outcomes; however, the current evidence lacks generalisability to general practitioners. It remains to be elucidated whether these favourable results can be replicated in a primary care setting. This study aims to address that gap by involving senior dental students undergoing supervised university education and training, with the potential to inform future best practice guidelines and promote the adoption of vital pulp therapy (VPT) as a predictable treatment alternative in the general dental population.\n\nThe clinical procedure involves complete caries-free excavation carried out under rubber dam isolation. After confirming vital pulp status-demonstrated by bleeding upon entry, participants will be randomised to receive one of two treatments: RCT or full pulpotomy.\n\nOutcomes will include clinical and radiographic success or failure of the intervention at 12 months. Additionally, patient-reported outcomes will be collected, specifically pain experienced and the use of analgesia during the immediate post-operative period (days 3 and 7).",[677,678],"Extremely Deep Caries","Pulpitis","2025-11-17",{"date":681,"type":49},"2025-11-21",{"date":683,"type":49},"2025-07-16",{"date":685,"type":20},"2027-07",{"name":55,"class":56},{"id":688,"slug":689,"hasResults":12,"nctId":690,"briefTitle":691,"officialTitle":691,"acronym":4,"eligibilityCriteria":692,"healthyVolunteers":12,"sex":16,"minAge":122,"maxAge":4,"enrollmentInfo":693,"targetDuration":4,"studyType":21,"phases":694,"briefSummary":695,"conditions":696,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":699,"lastUpdatePostDateStruct":700,"startDateStruct":702,"completionDateStruct":704,"leadSponsor":706,"locationsCount":87},"100611211","evaluating-the-feasibility-of-a-piezoelectric-smart-sensor-as-an-aid-to-help-clinicians-screen-for-the-development-of-pneumonia-in-an-at-risk-population-100611211","NCT07237633","Evaluating the Feasibility of a Piezoelectric Smart Sensor as an Aid to Help Clinicians Screen for the Development of Pneumonia in an At-risk Population","Inclusion Criteria:\n\n1. Aged 21 years and above\n2. Acute stroke patients (i.e. MRI or CT brain findings consistent with diagnosis) or ESRF patients on HD who are mentally competent and cognitively fit to provide consent.\n\nExclusion Criteria:\n\n1. Individuals who are unable to give informed consent\n2. Individuals with active dermatological conditions",{"count":156,"type":20},[23],"This proposed research aims to evaluate the feasibility of the piezoelectric sensor as an aid to help clinicians screen for the development of pneumonia in an at-risk population.",[697,698],"Stroke","End Stage Renal Failure on Dialysis","2025-11-16",{"date":701,"type":49},"2025-11-20",{"date":703,"type":49},"2023-01-18",{"date":705,"type":20},"2026-03-31",{"name":55,"class":56},""]